A 6-week, double-blind, randomized, fixed-dose, parallel-group study of the efficacy and safety of three dose levels of SM-13496 [lurasidone] compared to placebo and haloperidol in patients with schizophrenia who are experiencing an acute exacerbation of symptoms

Trial Profile

A 6-week, double-blind, randomized, fixed-dose, parallel-group study of the efficacy and safety of three dose levels of SM-13496 [lurasidone] compared to placebo and haloperidol in patients with schizophrenia who are experiencing an acute exacerbation of symptoms

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2005

At a glance

  • Drugs Haloperidol; Lurasidone
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top